Filing Flows › Comparisons › WEYS vs VNOV
Weyco Group vs VitaNova Life Sciences: WEYS and VNOV compared
Weyco Group is the larger company: $77.0M of revenue in its latest quarter (Q3 2026) against $322K for VitaNova Life Sciences (Q1 FY27). VitaNova Life Sciences is growing faster (+210% against +5% a year earlier). Weyco Group is more profitable, with an operating margin of 17.8% against -38.0%.
Where the money goes: WEYS and VNOV
Weyco Group (WEYS) · Q3 2026
Weyco Group, Q3 2026: revenue $77.0M (+5% year over year), operating margin 17.8%, net earnings $11.5M, operating cash flow $1.4M. The chart follows the revenue to costs, profit and cash.
VitaNova Life Sciences (VNOV) · Q1 FY27
VitaNova Life Sciences, Q1 FY27: revenue $322K (+210% year over year), operating margin -38.0%, net loss $123K, operating cash flow $7K. The chart follows the revenue to costs, profit and cash.
| Weyco Group (WEYS) | VitaNova Life Sciences (VNOV) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 FY27 |
| Revenue | $77.0M | $322K |
| Revenue growth, Y/Y | +5% | +210% |
| Gross margin | 49.7% | — |
| Operating margin | 17.8% | -38.0% |
| Net earnings | $11.5M | −$123K |
| Net margin | 14.9% | -38.3% |
| Operating cash flow | $1.4M | $7K |
| Free cash flow | $990K | — |
Where the revenue comes from
VitaNova Life Sciences
- Sale of Food Products: $235K (73%)
- Dietary Supplement Products: $87K (27%)
Questions
Which is bigger, Weyco Group or VitaNova Life Sciences?
Weyco Group is the larger company: $77.0M of revenue in its latest quarter (Q3 2026) against $322K for VitaNova Life Sciences (Q1 FY27).
Is Weyco Group or VitaNova Life Sciences growing faster?
VitaNova Life Sciences is growing faster (+210% against +5% a year earlier).
Which is more profitable, Weyco Group or VitaNova Life Sciences?
Weyco Group is more profitable, with an operating margin of 17.8% against -38.0%.
More: Weyco Group earnings · how Weyco Group makes money · VitaNova Life Sciences earnings · how VitaNova Life Sciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Sep 14, 2026). Fiscal quarters can end on different dates. Not investment advice.